FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, USA; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, Canada; 5Chang Gung University College of Medicine, Taoyuan, Taiwan; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; 8Department of Dermatology and Population Health Sciences, King’s College London, UK; 9Ada West Dermatology, St Luke’s Children’s Hospital Idaho, USA; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney, Australia; 11Eli Lilly and Company, Indianapolis, Indiana, USA; 12Almirall R&D, S.A., Barcelona, Spain; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
107PDF: 47 -
24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi1, M. Lebwohl2, A. Blauvelt3, C. Kartman4, C. Leatherwood4, K. Gordon5, N. Sattar6, L. Puig7, J. Merola8, K. Siu4, R. Wang4, L. Sun4, A. Leung9, N. Somani4, M. Rueda4, A. Cardoso4, M. Genovese4, A. Armstrong10, B. Strober11 | 1Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Blauvelt Consulting, LLC, Annapolis, MD, USA; 4Eli Lilly and Company, Indianapolis, IN, USA; 5Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; 6School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 7Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; 8Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 9Syneos Health, Morrisville, NC, USA; 10Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; 11Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA
101PDF: 33 -
04 | Association of a novel TERT polymorphism with poorer survival in male patients with melanoma Fortunato Cassalia1, Maria Santa Rocca2, Andrea Di Nisio3, Paolo del Fiore*4, Clara Benna5|7, Ilaria Cosci6, Simone Mocellin4|5, Alberto Ferlin*2|6 | 1Department of Dermatology, University of Padua, Padua; 2Unit of Andrology and Reproductive Medicine, University Hospital of Padua, Padua; 3Department of Wellbeing, Nutrition and Sport, Pegaso Telematic University, Naples; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 5Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 6Department of Medicine, University of Padua, Padua; 7Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
438 -
11 | Challenges in developing a digital pathology consultation network: insights from the MELCAYA experience Filippo Ugolini1, Dario Di Gangi2, Roberta Gugliotta3, Anna Szumera-Ciećkiewicz4|5, Llucia Alos6, Natalia Castrejón6, Stephan Forchhammer7, Barbara Valeri8, Nicolas Macagno9, Sule Ozturk Sari10, Ozge Hurdogan10, Sokol Sina11, Sylvie Fraitag12, Valerio Gaetano Vellone13, Chiara Trambaiolo13, Rita Alaggio14, Sabrina Rossi14, Giovanni Arcuri3, Daniela Massi2, Claudio Conti3 | 1Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy. 2Section of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy. 3UOC Direzione Tecnica, ICT ed Innovazione Tecnologie Sanitarie, Fondazione Policlinico Agostino Gemelli IRCCS, Roma, Italy. 4Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 5Department of Pathology , Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 6Department of Pathology, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.7Department of Dermatology, University Medical Center, Eberhard Karls University Tübingen, Tübingen, Germany. 8Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 9Aix-Marseille University, Marmara Institute, INSERM, U1251, MMG, DOD-CET, Marseille, France. 10Department of Pathology, Istanbul University Istanbul Medical Faculty, Istanbul, Türkiye; 11Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 12Pathology Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; 13Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa; 14Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
468 -
Dermoscopic features of Monkeypox virus skin infection
1004PDF: 494HTML: 77 -
56 | FIRST-LINE EXTRACORPOREAL PHOTOPHERESIS PLUS INTERFERON-Α IN SÉZARY SYNDROME: REAL-WORLD SURVIVAL AND EXPLORATORY BLOOD BIOMARKERS A. Di Guardo1, M.P. Accetturi1, C. Cristofoletti1, A. Frezzolini1, E. Scala1, L. Fania1|2, A. Monopoli1, M.G. Narducci1 | 1IDI-IRCCS, Dermatological Research Hospital, Italy; 2Department of Life Science, Health, and Health Professions, Link University of Rome, Italy
93PDF: 108 -
34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo1|2, Bruna Dalmasso3, Maria Chiara Scaini4, Laura Cendron5, Monica Rodolfo6, Ilaria Mattavelli7, Elena Tamborini8, Francesca Collina9, Gerardo Ferrara, Gabriele Madonna10, Carlo Cota11, Elisa Melucci12, Stefania Tommasi13, Martina Ubaldi14, Roberta Depenni15, Andrea Carugno16, Riccardo Marconcini17, Laura Orgiano18, Maurizio Lombardo19, Simona Sola20, Cristina Pellegrini21, Francesca Castiglione22, Matteo Gasparotto5|23, Alireza Jorkesh5, Stefania Pellegrini4, Edoardo Raposio1, Andrea Boutros2, Enrica Teresa Tanda2, Michele Guida25, Pietro Quaglino26, Giuseppe Palmieri27, Daniela Massi22, Paolo Antonio Ascierto10, Mario Mandalà*28, Chiara Menin*4, Paola Ghiorzo*24, Lorenza Pastorino*24, for the Italian Melanoma Intergroup29 | 1Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; 2IRCCS Ospedale Policlinico San Martino, Genova; 3IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; 4Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; 5Department of Biology, University of Padua, Padua; 6Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 7Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 8Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 9Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; 10Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; 11Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; 12Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; 13Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; 14Unit of Medical Oncology, University of Perugia; 15Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; 16Department of Medicine and Surgery, University of Insubria, Varese; 17Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; 18Department of Medical Oncology, University of Cagliari, Cagliari; 19Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; 20Surgical Pathology, Galliera Hospital, Genoa; 21Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; 22Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; 23Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 24Department of Internal Medicine and Medical Specialties, University of Genoa; 25Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; 26Dermatology Clinic, Department of Medical Sciences, University of Turin; 27Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; 28University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; 29Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.
414 -
26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL E. Filippi1, J. F. Merola2, P. Mease3, A. Kivitz4, N. Sattar5, L. C. Coates6, C. E. Kartman7, P. Fischer7, L. Sun7, A. Cardoso7, M. C. Genovese7, A. Ogdie8 | 1Eli Lilly Italia S.p.A, Florence, Italy; 2Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 3Providence Swedish Medical Center, Seattle, WA, USA; 4Altoona Center for Clinical Research, Duncansville, PA, USA; 5School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 7Eli Lilly and Company, Indianapolis, IN, USA; 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
102PDF: 28 -
55 | PAEDIATRIC FOLLICULAR MUCINOSIS WITHOUT PROGRESSION TO MYCOSIS FUNGOIDES: A LONG-TERM CLINICOPATHOLOGIC STUDY A. Di Guardo1, L. Ambrosio1|2, M. Testa1, D. Didona1, F. Moro1|2, A. Rallo1, G. Di Lella1, L. Colonna1, S. Pallotta1, A. Panebianco1, L. Fania1|3 | 1IDI-IRCCS, Dermatological Research Hospital, Rome, Italy; 2UOC of Dermatology, Department of Medical and Cardiovascular Sciences, “Sapienza” University of Rome, Italy; 3Department of Life Science, Health, and Health Professions, Link University of Rome, Italy
83PDF: 110
